anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12345678910111213...4142»
  • ||||||||||  Memory mayhem: Hormone therapy causing brain fog in patients with DCIS. (Hall A; Poster Bd #: 167) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1303;    
    The limitation of the study is the duration of follow up. Usually, patients with DCIS live much longer and can have cognitive effects beyond the window of this study; hence a prospective long-term follow-up study is required to ascertain the relation of HT and cognitive side effects.
  • ||||||||||  anastrozole / Generic mfg., exemestane / Generic mfg.
    Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27. (Hall A; Poster Bd #: 159) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1295;    
    P3
    DDFS was superior for patients with higher ER and PgR standardized units compared with those with HSCOREs and %+ <-1. The adjunctive statistical standardization of ER and PgR performed here is similar to that mandated for clinical practice by the World Health Organization for BMD.
  • ||||||||||  Orilissa (elagolix) / AbbVie
    Trial completion date:  Brain Blood Flow Responses to Stress: Sex Differences (clinicaltrials.gov) -  Apr 23, 2024   
    P4,  N=26, Recruiting, 
    When used in addition to rhGH therapy in boys with GHD and advanced BA, AIs were observed to slow down the tempo of BA maturation after 1 Trial completion date: Apr 2025 --> May 2026
  • ||||||||||  Retrospective data, Review, Journal:  Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Mar 28, 2024   
    Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial initiation date:  TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov) -  Mar 25, 2024   
    P2,  N=90, Recruiting, 
    However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia. Initiation date: Feb 2024 --> Oct 2023
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Journal:  Ribociclib plus Endocrine Therapy in Early Breast Cancer. (Pubmed Central) -  Mar 24, 2024   
    P3
    Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).
  • ||||||||||  Navigating Sexuality and Hormone Therapy in Early Luminal Breast Cancer (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_527;    
    Our study shows the strong link between sexual dysfunction and HT in Luminal eBC. This AEs emphasize the need for tailored support, personalized approaches and integrated sexual counseling, improving patients QoL and outcomes.
  • ||||||||||  giredestrant (GDC-9545) / Roche, Verzenio (abemaciclib) / Eli Lilly
    NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer (GIM31-Neo-AGILE trial) (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_413;    
    Secondary outcomes include percent change in Ki67 expression from baseline to W2, ROR score reduction (from baseline to W2 and surgery), clinical and radiologic (magnetic resonance imaging) objective responses, safety, and quality of life assessments. Exploratory endpoints are mechanisms of response and resistance to therapy, the correlation between gut/loco regional microbiome and response to treatment, the correlation between Ki-67% reduction and 18-Fluorothymidine (FLT) uptake reduction and pathological complete response rate (ypT0/is, ypN0) of G plus A.
  • ||||||||||  giredestrant (GDC-9545) / Roche
    A Window-of-Opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC) (IBCSG 67-22; PREcoopERA) (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_412;    
    P2
    Background: Adjuvant endocrine therapy (ET) for premenopausal women with ER+/HER2- EBC often includes ovarian function suppression (OFS) via a GnRH or LHRH agonist (LHRHa) plus an aromatase inhibitor (AI) or tamoxifen...Trial design: PREcoopERA is a randomized, open-label, 3-arm, WOO trial evaluating the anti-proliferative activity and safety of the oral SERD giredestrant +/- LHRHa triptorelin, as compared to the AI anastrozole + triptorelin...The first woman was enrolled on 25 January 2024. The PREcoopERA trial is sponsored and coordinated by ETOP IBCSG PartnersFoundation in collaboration with F. Hoffmann-La Roche Ltd.
  • ||||||||||  anastrozole / Generic mfg.
    SITOSTEROLAEMIA IN A 12-YEAR-OLD CHILD WITH SHORT STATURE (Umm Al Quwain hall) -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_603;    
    To mitigate the effects of puberty on his height and to delay bone closure, he was treated with a GnRH analogue and anastrozole... This case highlights the necessity of considering sitosterolaemia in the differential diagnosis of short stature and incorporating lipid profile in the initial work up.
  • ||||||||||  anastrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism (clinicaltrials.gov) -  Mar 15, 2024   
    P4,  N=120, Recruiting, 
    This case highlights the necessity of considering sitosterolaemia in the differential diagnosis of short stature and incorporating lipid profile in the initial work up. Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2025
  • ||||||||||  Hiltonol (poly-ICLC) / Oncovir
    Enrollment open, Trial completion date:  Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov) -  Mar 12, 2024   
    P1,  N=50, Recruiting, 
    From the perspective of Chinese payers, dalpiciclib plus NSAI appears to be a cost-effective strategy compared with abemaciclib plus NSAI for the first-line treatment of patients with HR+/HER2- ABC in China. Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Aug 2028
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Computational inhibition of aromatase: an enzyme associated with endometriosis | Poster Board #1715 (In-person; Poster Board #1715; Hall C (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_9873;    
    Our research was able to narrow down the pool of nearly 3000 isoflavanones to 5 molecules. These results reveal promising novel drug treatments for endometriosis through targeting aromatase.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients (Section 46) -  Mar 5, 2024 - Abstract #AACR2024AACR_5156;    
    Background: AIs, such as letrozole, anastrozole, and exemestane, are used to treat hormonal receptor positive (HR+) breast cancer (BC) patients. This study provides insights into the genetic basis of resistance to AIs in mBC patients, opening up possibilities for development of new treatments to overcome resistance.
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Enrollment closed:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Mar 5, 2024   
    P1,  N=396, Active, not recruiting, 
    This study provides insights into the genetic basis of resistance to AIs in mBC patients, opening up possibilities for development of new treatments to overcome resistance. Recruiting --> Active, not recruiting
  • ||||||||||  anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Journal:  Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers. (Pubmed Central) -  Feb 23, 2024   
    This study strongly emphasizes the importance of considering specific glycan traits to comprehend the dynamic mechanisms driving breast cancer progression and the effects of targeted therapies. The nuanced differences observed in glycan modifications between these two treatments underscore the necessity for further comprehensive research aimed at thoroughly evaluating the long-term implications and therapeutic efficacy for breast cancer patients.
  • ||||||||||  anastrozole / Generic mfg.
    A Case of Sarcomatoid Carcinoma Presenting in the Setting of Anastrozole Use (San Diego Convention Center, Area J (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6925;    
    Several similar cases of sarcoidosis like reactions from checkpoint inhibitors have been previously presented in the literature. The present case highlights a unfortunate but relatively unique clinical manifestation of pulmonary sarcomatoid carcinoma after treatment with anastrozole not well documented in prior literature.
  • ||||||||||  anastrozole / Generic mfg.
    A Pulmonary Sarcoidosis Case: A Mimicker of Metastatic Disease (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6266;    
    She underwent radioactive seed localized right partial mastectomy followed by radiation therapy and anastrazole chemotherapy with good response...Distinguishing between metastatic disease and sarcoidosis in breast cancer patients can be challenging as both pathologies may present with mediastinal lymphadenopathy or opacities. Histological confirmation by EBUS guided lymph node biopsy satisfies one of the major criteria for the diagnosis of sarcoidosis and should be considered in breast cancer patients with new abnormal pulmonary findings, to rule out metastatic disease recurrence and guide future therapies.
  • ||||||||||  denifanstat (TVB-2640) / Sagimet Biosci
    Enrollment closed, Enrollment change:  TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) -  Feb 18, 2024   
    P2,  N=19, Active, not recruiting, 
    Histological confirmation by EBUS guided lymph node biopsy satisfies one of the major criteria for the diagnosis of sarcoidosis and should be considered in breast cancer patients with new abnormal pulmonary findings, to rule out metastatic disease recurrence and guide future therapies. Recruiting --> Active, not recruiting | N=80 --> 19